Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$7.89
-0.1%
$7.30
$5.90
$34.11
$580.28M2.171.46 million shs826,658 shs
FibroGen, Inc stock logo
FGEN
FibroGen
$5.69
+8.4%
$7.16
$4.50
$38.25
$22.67M0.7476,019 shs33,072 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$5.03
+0.1%
$4.44
$2.64
$5.92
$3.18B0.81187,081 shs2.73 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$172.36
$171.30
$21.83
$172.46
$6.58B1.421.09 million shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%+4.66%+13.54%+20.29%-66.98%
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%+9.00%-25.40%-18.71%-67.06%
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00%+3.62%+10.46%+39.99%-1.80%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%+4.18%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arvinas, Inc. stock logo
ARVN
Arvinas
3.1128 of 5 stars
4.32.00.00.00.02.51.3
FibroGen, Inc stock logo
FGEN
FibroGen
4.7157 of 5 stars
3.33.00.04.74.43.30.6
Hypermarcas stock logo
HYPMY
Hypermarcas
N/AN/AN/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.55
Moderate Buy$20.29157.12% Upside
FibroGen, Inc stock logo
FGEN
FibroGen
2.50
Moderate Buy$250.004,293.67% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MOR, FGEN, RETA, ARVN, and HYPMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$24.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.00
6/1/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/15/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $21.00
5/13/2025
FibroGen, Inc stock logo
FGEN
FibroGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$250.00 ➝ $250.00
5/9/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.00
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.50
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.00
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$21.00 ➝ $11.00
5/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$16.00
5/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$263.40M2.19N/AN/A$8.17 per share0.97
FibroGen, Inc stock logo
FGEN
FibroGen
$29.62M0.78N/AN/A($50.89) per share-0.11
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.31$0.47 per share10.64$3.54 per share1.42
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$23.48M280.05N/AN/A($1.79) per share-96.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)
FibroGen, Inc stock logo
FGEN
FibroGen
-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)
Hypermarcas stock logo
HYPMY
Hypermarcas
$248.62M$0.2420.94N/A12.51%6.95%3.34%7/23/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
-$311.90MN/A0.00N/AN/AN/A-922.50%-73.39%N/A

Latest MOR, FGEN, RETA, ARVN, and HYPMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.87N/AN/AN/A$34.42 millionN/A
5/12/2025Q1 2025
FibroGen, Inc stock logo
FGEN
FibroGen
$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million
5/1/2025Q1 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.93$1.14+$2.07$1.14$41.87 millionN/A
4/23/2025Q1 2025
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A-$0.04N/A-$0.04N/A$184.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.142.79%N/A58.33%N/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/A

Latest MOR, FGEN, RETA, ARVN, and HYPMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.03452.81%6/30/20257/1/20251/8/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.58
4.58
FibroGen, Inc stock logo
FGEN
FibroGen
N/A
2.02
1.98
Hypermarcas stock logo
HYPMY
Hypermarcas
0.63
1.26
0.80
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.84
3.21
3.19

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
FibroGen, Inc stock logo
FGEN
FibroGen
72.71%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
4.73%
FibroGen, Inc stock logo
FGEN
FibroGen
3.07%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
26.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
42072.99 million69.54 millionOptionable
FibroGen, Inc stock logo
FGEN
FibroGen
5704.04 million3.92 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481633.42 millionN/ANot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
32138.15 million27.93 millionOptionable

Recent News About These Companies

Reta Hendrickson

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arvinas stock logo

Arvinas NASDAQ:ARVN

$7.89 -0.01 (-0.11%)
Closing price 07/3/2025 02:37 PM Eastern
Extended Trading
$7.96 +0.07 (+0.87%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

FibroGen stock logo

FibroGen NASDAQ:FGEN

$5.69 +0.44 (+8.38%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$5.61 -0.08 (-1.41%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$5.03 +0.01 (+0.12%)
As of 07/3/2025 12:21 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 07/3/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Reata Pharmaceuticals stock logo

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.